BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:NRM-823 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of NRM-823\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07182149-2642@assetmemo.bio
DTSTAMP:20261121T005411Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:NRM-823: Phase 1 readout est. (NCT07182149)
DESCRIPTION:NRM-823\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A Phase
  1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Re
 fractory Solid Tumors\nEstimated primary completion: 30 May 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/nrm-823#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07182149
URL:https://assetmemo.bio/drug/nrm-823#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
